An observational study in Heart Transplant, sponsored by Xie Mingxing. Status unknown. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-26.
Sponsored by Xie Mingxing · Observational
The aim of this study is to evaluat the impact of diabetes on cardiac function in patients with heart transplantation by multimodal imaging and analyse their prognosis.
This study is planed to enroll 300000 patients after heart transplantation, all the patients will be divided into 3 groups according to whether or not they have diabetes and when did they develop diabete. Echocardiography will be used to evaluat their cardiac function. Comparing their cardiac function and clinical information and analysing their prognosis to evaluat the impact of diabetes.
Xie Mingxing is the lead sponsor of 5 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Adult patients who received a heart transplant after 2015
Exclusion Criteria:
patients who underwent heart tranplantation without diabetes
patients who underwent heart tranplantation with diabetes before the transplantation
patients who underwent heart tranplantation without diabetes until after the transplantation
all-cause mortality
death from all causes
Time frame: up to 2023.12
acute rejection
acute rejection required treatment
Time frame: up to 2023.12
readmission
readmission from all causes
Time frame: up to 2023.12
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
This study is status unknown, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Xie Mingxing